OncoSKY and PancreaSeq advance molecular triage
What happened
- OncoSKY highlighted evidence that circulating tumor DNA blood tests can catch mutations tissue biopsies miss when cancers vary across sites and change over time. - A 241-patient PancreaSeq Genomic Classifier study reported 94.6% sensitivity for mucinous cysts and 86.6% sensitivity for advanced neoplasia, with specificity above 96%. - Both point to earlier molecular testing from limited samples before surgery or repeat biopsy. (nature.com)
Why it matters
Cancer testing still often relies on a tiny tissue sample, even when a tumor can differ from one spot to another and change after treatment. Blood-based circulating tumor DNA tests are built to sample those fragments in real time. (mdpi.com) (nature.com) That is the point behind OncoSKY’s explainer on why liquid biopsy can find mutations a tissue biopsy misses. Reviews published in 2025 say tissue can give only a local, static snapshot, while circulating tumor DNA can reflect spatial heterogeneity and clonal evolution. (nature.com) (mdpi.com) One 2025 comparative study matched pre-mortem liquid biopsy with 56 postmortem tissue samples from eight patients with solid tumors. The liquid biopsy profiles overlapped with tissue mutations by 33% to 92% and also identified resistance mutations tissue sampling had overlooked. (mdpi.com) Pancreatic cysts pose a related sampling problem: many are found on imaging, but only a minority are cancerous or on a path toward cancer. The fluid collected by endoscopic ultrasound-guided fine-needle aspiration is often scant, so every test competes for the same small specimen. (pancreaseq.com) (nordx.testcatalog.org) A multi-institutional validation study published on December 12, 2025 tested the PancreaSeq Genomic Classifier on 241 patients with follow-up diagnoses. The assay combines DNA and RNA sequencing to classify cyst type and estimate malignant potential from pancreatic cyst fluid. (link.springer.com) (pmc.ncbi.nlm.nih.gov) In that cohort, PancreaSeq Genomic Classifier reached 94.6% sensitivity and 96.4% specificity for mucinous cysts, with an area under the curve of 0.955. For advanced neoplasia, defined as high-grade dysplasia or pancreatic ductal adenocarcinoma, sensitivity was 86.6% and specificity was 97.9%. (link.springer.com) The same paper said older markers performed worse on sensitivity. Increased fluid viscosity, carcinoembryonic antigen, worrisome imaging features, malignant cytopathology, and high-risk stigmata all posted lower sensitivity or lower area-under-the-curve values in the head-to-head comparison. (link.springer.com) The classifier also improved on the earlier DNA-only PancreaSeq assay. The study reported statistically higher sensitivity for mucinous cysts with PancreaSeq Genomic Classifier at p below 0.001 and for advanced neoplasia at p equals 0.031, while specificity remained high. (link.springer.com) A separate Gastrointestinal Endoscopy study, posted in 2025, looked at 441 adults seen in a high-risk pancreatic lesion clinic from 2016 to 2022. It evaluated how next-generation sequencing results were used in management decisions, including surgery and cyst-type differentiation. (giejournal.org) Taken together, the liquid-biopsy and pancreatic-cyst data push the same workflow change: run molecular testing earlier, before limited material is exhausted by repeat passes or broad workups. The practical goal is triage — deciding which patients need surgery, which need surveillance, and which need more targeted follow-up testing. (nature.com) (link.springer.com)
Key numbers
- A 241-patient PancreaSeq Genomic Classifier study reported 94.6% sensitivity for mucinous cysts and 86.6% sensitivity for advanced neoplasia, with specificity above 96%.
- Reviews published in 2025 say tissue can give only a local, static snapshot, while circulating tumor DNA can reflect spatial heterogeneity and clonal evolution.
- (nature.com) (mdpi.com) One 2025 comparative study matched pre-mortem liquid biopsy with 56 postmortem tissue samples from eight patients with solid tumors.
- The liquid biopsy profiles overlapped with tissue mutations by 33% to 92% and also identified resistance mutations tissue sampling had overlooked.
What happens next
- It evaluated how next-generation sequencing results were used in management decisions, including surgery and cyst-type differentiation.
Quick answers
What happened in OncoSKY and PancreaSeq advance molecular triage?
OncoSKY highlighted evidence that circulating tumor DNA blood tests can catch mutations tissue biopsies miss when cancers vary across sites and change over time. A 241-patient PancreaSeq Genomic Classifier study reported 94.6% sensitivity for mucinous cysts and 86.6% sensitivity for advanced neoplasia, with specificity above 96%. Both point to earlier molecular testing from limited samples before surgery or repeat biopsy. (nature.com)
Why does OncoSKY and PancreaSeq advance molecular triage matter?
Cancer testing still often relies on a tiny tissue sample, even when a tumor can differ from one spot to another and change after treatment. Blood-based circulating tumor DNA tests are built to sample those fragments in real time. (mdpi.com) (nature.com) That is the point behind OncoSKY’s explainer on why liquid biopsy can find mutations a tissue biopsy misses. Reviews published in 2025 say tissue can give only a local, static snapshot, while circulating tumor DNA can reflect spatial heterogeneity and clonal evolution. (nature.com) (mdpi.com) One 2025 comparative study matched pre-mortem liquid biopsy with 56 postmortem tissue samples from eight patients with solid tumors. The liquid biopsy profiles overlapped with tissue mutations by 33% to 92% and also identified resistance mutations tissue sampling had overlooked. (mdpi.com) Pancreatic cysts pose a related sampling problem: many are found on imaging, but only a minority are cancerous or on a path toward cancer. The fluid collected by endoscopic ultrasound-guided fine-needle aspiration is often scant, so every test competes for the same small specimen. (pancreaseq.com) (nordx.testcatalog.org) A multi-institutional validation study published on December 12, 2025 tested the PancreaSeq Genomic Classifier on 241 patients with follow-up diagnoses. The assay combines DNA and RNA sequencing to classify cyst type and estimate malignant potential from pancreatic cyst fluid. (link.springer.com) (pmc.ncbi.nlm.nih.gov) In that cohort, PancreaSeq Genomic Classifier reached 94.6% sensitivity and 96.4% specificity for mucinous cysts, with an area under the curve of 0.955. For advanced neoplasia, defined as high-grade dysplasia or pancreatic ductal adenocarcinoma, sensitivity was 86.6% and specificity was 97.9%. (link.springer.com) The same paper said older markers performed worse on sensitivity. Increased fluid viscosity, carcinoembryonic antigen, worrisome imaging features, malignant cytopathology, and high-risk stigmata all posted lower sensitivity or lower area-under-the-curve values in the head-to-head comparison. (link.springer.com) The classifier also improved on the earlier DNA-only PancreaSeq assay. The study reported statistically higher sensitivity for mucinous cysts with PancreaSeq Genomic Classifier at p below 0.001 and for advanced neoplasia at p equals 0.031, while specificity remained high. (link.springer.com) A separate Gastrointestinal Endoscopy study, posted in 2025, looked at 441 adults seen in a high-risk pancreatic lesion clinic from 2016 to 2022. It evaluated how next-generation sequencing results were used in management decisions, including surgery and cyst-type differentiation. (giejournal.org) Taken together, the liquid-biopsy and pancreatic-cyst data push the same workflow change: run molecular testing earlier, before limited material is exhausted by repeat passes or broad workups. The practical goal is triage — deciding which patients need surgery, which need surveillance, and which need more targeted follow-up testing. (nature.com) (link.springer.com)
